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ABSTRACT 
The identification of cancer-associated long non-coding RNAs (lncRNAs) and the 
investigation of their molecular and biological functions are important to understand the molecular 
biology of cancer and its progression. Although the functions of lncRNAs and the mechanisms 
regulating their expression are largely unknown, recent studies are beginning to unravel their 
importance in human health and disease. Here, we report that a number of lncRNAs are 
differentially expressed in melanoma cell lines in comparison to melanocytes and keratinocyte 
controls. One of these lncRNAs, SPRY4-IT1 (GenBank accession ID AK024556), is derived from 
an intron of the SPRY4 gene and is predicted to contain several long hairpins in its secondary 
structure. RNA-FISH analysis showed that SPRY4-IT1 is predominantly localized in the 
cytoplasm of melanoma cells, and SPRY4-IT1 RNAi knockdown results in defects in cell growth, 
differentiation and higher rates of apoptosis in melanoma cell lines. Differential expression of both 
SPRY4 and SPRY4-IT1 was also detected in vivo, in 30 distinct patient samples, classified as 
primary in situ, regional metastatic, distant metastatic, and nodal metastatic melanoma. The 
elevated expression of SPRY4-IT1 in melanoma cells compared to melanocytes, its accumulation 
in cell cytoplasm, and effects on cell dynamics, including increased rate of wound closure upon 
SPRY4-IT1 overexpression, suggest that the higher expression of SPRY4-IT1 may have an 
important role in the molecular etiology of human melanoma.  
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INTRODUCTION 
There is considerable interest in understanding the function of RNA transcripts that do not 
code for proteins in eukaryotic cells. As evidenced by cDNA cloning projects (1) and genomic 
tiling arrays (2), more than 90% of the human genome undergoes transcription, but does not code 
for proteins. These transcriptional products are referred to as non-protein coding RNAs (ncRNAs). 
A variety of ncRNAs, such as ribosomal RNAs, transfer RNAs, and spliceosomal RNAs, are 
essential for cell function. Similarly, large numbers of short ncRNAs such as micro-RNAs 
(miRNAs), endogenous short interfering RNAs (siRNAs), PIWI-interacting RNAs (piRNAs) and 
small nucleolar RNAs (snoRNAs) are also known to play important regulatory roles in eukaryotic 
cells. Recent studies have demonstrated that the mammalian genome expresses large numbers 
of long ncRNAs (lncRNA) (1) that are dynamically expressed in tissue-, differentiation stage- and 
cell type-specific patterns (3), at least some of which localize into specific subcellular 
compartments (3, 4). lncRNAs are also known to play an important roles during cellular 
development and differentiation (5-8) consistent with the view that they are under evolutionary 
selection (9-11). Interestingly, lncRNAs can influence the expression of specific target proteins at 
specific genomic loci (12, 13), modulate the activity of protein binding partners (14, 15), direct 
chromatin-modifying complexes to their sites of action (16), and are post-transcriptionally 
processed to produce numerous 5′-capped small RNAs (17, 18). Epigenetic pathways can also 
regulate the differential expression of lncRNAs (19). The expression of lncRNAs is misregulated 
in various diseases, including ischaemia (20), heart disease (21), Alzheimer's disease (22), 
psoriasis (23), and spinocerebellar ataxia type 8 (19, 24). This misregulation has also been 
shown in various types of cancers, such as breast cancer (8, 25), colon cancer (26), prostate 
cancer (27), hepatocellular carcinoma (28, 29) and leukemia (28). One such lncRNA, DD3 (also 
known as PCA3), is listed as a prostate cancer-specific biomarker (30). Recent studies have 
revealed the contribution of ncRNAs as proto-oncogenes, e.g. GAGE6 (31), as tumor suppressor 
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genes, e.g. p15 (32), in tumorigenesis, and as drivers of metastatic transformation, e.g. HOTAIR 
in breast cancer (33).  
The focus of this study was to identify and characterize lncRNAs that are differentially 
expressed in melanoma compared to melanocytes and normal skin. We find that a group of 
lncRNAs is differentially regulated in melanoma and one such lncRNA, SPRY4-IT1, derived from 
an intron within the SPRY4 gene, is upregulated in melanoma cells. Knocking-down its 
expression resulted in defects in cell growth, differentiation and elevated rates of apoptosis in 
melanoma cells.  
 
MATERIALS AND METHODS 
RNA secondary structure prediction 
The most recent versions of RNAfold (34) and RNAstructure (35) were employed for 
generating RNA secondary structures. Both of these programs implement an RNA partition 
function algorithm, which was chosen for two reasons: (i) it produces a structure almost identical 
to the minimum free energy algorithm with RNAfold with few proximal sub-optimal structures, and 
(ii) it is required for subsequent prediction of pseudoknots with ProbKnot (included in 
RNAstructure).  
The evolutionary conservation of secondary structures was conducted with the consensus-
based programs RNAz (36) and SISSIz (37) on the Enredo-Pecan-Ortheus 31-way eutherian 
mammal genome alignment from ENSEMBL. Orthologous sequences to SPRY4-IT1 were 
selected and realigned with MAFFT using the mafft-ginsi algorithm (38). Sliding window ranges of 
100 nt window with 25 nt slide, 150 nt window with 50 nt slide, and 300 nt window with 100 nt 
slide were tested with both RNAz and SISSIz, using parameters “-d” and “-d –t –n 200 -p 0.02”, 
respectively. 
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siRNA to knockdown SPRY4-IT1 in melanoma cells 
Five different siRNA™ siRNAs that targeted SPRY4-IT1 RNA and a Scrambled siRNA™ 
siRNA control were generously provided by Life Technologies. The siRNA™ siRNA molecules 
are 25 base-pair double-stranded RNA oligonucleotides with proprietary chemical modifications. 
The BLOCK-iT RNAi designer was used to find gene-specific 25 nucleotide siRNA™ siRNA 
molecules. It uses gene-specific targets for RNAi analysis and reports up to 10 top scoring 
siRNA™ siRNA targets. The freeze-dried siRNAs were dissolved in RNase free-water and stored 
as aliquots at −20°C. The siRNA with the sequence GCTTTCTGATTCCAAGGCCTATTAA 
yielded the highest degree of SPRY4-IT1-knockdown. 
Overexpression construct to up-regulate SPRY4-IT1 in LOX-IMV1 melanoma cell line 
Oligonucleotides for amplification of full length SPRY4-IT1 (SPRY4-IT1 Forward 5’-
TAAGCTTGTAGAGATGGGGGTTTCATCCTGTTGG-3’ and SPRY4-IT1 Reverse 5’- 
ACTCGAGAAAGACTCCCTTTCCTTAAGCAGATTCAC-3’) were designed to incorporate external 
HindIII and XhoI sites respectively. The melanocyte genomic DNA SPRY4-IT1 amplicon 
(Amplitaq Gold, Life Technologies) was cloned into the pCR4-TOPO vector (Life Technologies), 
sequence verified and subcloned via HindIII/XhoI digestion into the pcDNA6/V5-HisA mammalian 
expression vector (Life Technologies) 
Cell culture conditions and transfection  
siRNA transfection was performed with lipofectamine™ RNAiMax (Life Technologies) in 6 well 
plates. 6, 12 and 18 nM RNAi duplexes were diluted in 500 μL serum free medium, mixed gently 
and 5 μL of lipofectamine™ RNAiMAX was added to each well containing the diluted RNAi 
molecules. This mixture was incubated for 20 min at room temperature before the transfection. 
250,000 cells were diluted in complete Tu growth medium (39) (without antibiotics) and plated in 
each well.  RNAi duplex - lipofectamine™ RNAiMAX complexes were added to each well and 
mixed gently by rocking the plate. Plasmid transfection was performed in MatTek 1.5 mm glass-
bottom dishes. 5 μg of pcDNA6/SPRY4-IT1 or pcDNA6/V5-HisA (negative contol) was diluted in 
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100 μL serum free medium to which 5 μL of Fugene 6 was added. Following a 20 minute 
incubation, the respective transfection mixtures were added their respective dishes.  In all cases, 
cells were incubated for 48 h at 37°C in a CO2 incubator and gene knockdown or overexpression 
levels were assessed by qRT-PCR. 
In vitro wound healing assay 
WM1552C cells were transfected with 18 nM SPRY4-IT1 or Scrambled siRNATM siRNA (Life 
Technologies), respectively, and LOX IMV1 cells were transfected with pcDNA6/SPRY4-IT1 or 
empty pcDNA6/V5-HisA respectively, as described above. All transfected cell samples were 
seeded on Mat Tek 1.5 mm glass-bottom dishes until 90-95% confluent. Cell monolayers were 
then gently scratched with a pipette tip across the diameter of the dish and rinsed with PBS and 
cell media to remove cellular debris. The surface area of the scratched surface was quantified 
after wounding and again every 20 min for 24 h on a Nikon BioStation IM (Nikon Instruments, 
Inc., Japan) cell incubator. The extent of wound closure was calculated using the ratio of the 
surface area between the remaining wound edges to the surface area of the initial wound for 
each time point. These data were then expressed as a percentage of wound closure relative to 
control conditions for each experiment. The change in surface area was calculated using NIS 
Elements software (Nikon Instruments, Inc., Japan) and performed in triplicate. 
RNA-FISH analysis 
Locked nucleic acid (LNA)-modified probes for human lncRNA SPRY4-IT1 (5-FAM- 
TCCACTGGGCATATTCTAAAA -36-FAM) and a negative/Scramble control (5TYE665-
GTGTAACACGTCTATACGCCCA-3 TYE665, miRCURY-LNA detection probe, Exiqon) were 
used for RNA in situ hybridization (RNA-FISH). In situ hybridization was performed using the 
RiboMap in situ hybridization kit (Ventana Medical Systems Inc.) on a Ventana machine. The cell 
suspension was diluted to 10,000 cells/100 µL and pipetted into clonal rings on the autoclaved 
glass slides. The following day, the clonal rings were removed; slides were washed in PBS and 
fixed in 4% paraformaldehyde and 5% acetic acid. After acid treatment using hydrochloride-based 
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RiboClear reagent (Ventana Medical Systems) for 10 min at 37°C, the slides were treated with 
the ready-to-use protease 3 reagent. The cells were hybridized with the antisense LNA riboprobe 
(40 nM) using RiboHybe hybridization buffer (Ventana Medical Systems) for 2 h at 58°C after an 
initial denaturing prehybridization step for 4 min at 80°C. Next, the slides were subjected to a low-
stringency wash with 0.1X SSC (Ventana Medical Systems) for 4 min at 60°C, and then two 
further washing steps with 1X SSC for 4 min at 60°C. These slides were fixed in RiboFix and 
counterstained with 4’-6’diamidino-2-phenylindole (DAPI), in an antifade reagent (Ventana). The 
images were acquired using a Nikon A1R VAAS laser point- and resonant-scanning confocal 
microscope equipped with a single photon Ar-ion laser at 60X with 4X zoom. 
Metabolic viability by MTT assay 
MTT (3-(4,5-dimethyl-2-yl)-2,5-diphenyl-2II-tetrazolium bromide) was purchased from Roche. 
Cells were plated in 96 well plates (5000 cells/100 µL/well). After 48 h of transfection, 20 µL MTT 
solution was added and the cells were incubated at 37°C in the dark for 4 h. The generated 
formazan OD was measured at 490 nm to determine the cell viability on the Flex station 
(Molecular Devices; www.moleculardevices.com).  
Invasion assays 
BD BioCoat™ growth factor reduced insert plates (Matrigel™ Invasion Chamber 12 well 
plates) were prepared by rehydrating the BD Matrigel™ matrix coating in the inserts with 0.5 mL 
of serum-free complete Tu media for 2 h at 37°C. The re-hydration solution was carefully 
removed from the inserts, 500 µL complete Tu (2% FBS) was added to the lower wells of the 
plate. 1 x 104 transfected and untransfected cells suspended in 500 µL of serum-free complete Tu 
media was added to the top of each insert well. Invasion assay plates were incubated for 48 h at 
37°C. Following incubation, the non-invading cells were removed by scrubbing the upper surface 
of the insert. The cells on the lower surface of the insert were stained with crystal violet and each 
trans-well membrane mounted on a microscope slide for visualization and analysis. The slides 
were scanned in Scanscope and the number of cells migrating was counted using Aperio 
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software (www.aperio.com). Data are expressed as the percent invasion through the membrane 
relative to the migration through the control membrane. 
See supplementary material (S10) for RNA extraction, Microarray analysis, Quantitative Real-
time PCR, Northern blot analysis and pPhosphatidylserine externalization,  
 
RESULTS 
Differentially regulated lncRNAs in melanoma cells 
To identify lncRNAs involved in melanoma, we analyzed total RNA from a stage III melanoma 
cell line (WM1552C), melanocytes and keratinocytes by using a noncoding RNA microarray 
(NCode human array; Life Technologies). The microarrays contain probes to target 12,784 
lncRNAs and 25,409 mRNAs. In total, we identified 77 lncRNAs that were significantly 
differentially expressed (P < 0.015; fold-change > 2) in WM1552C relative to melanocytes. In 
addition to cell line profiling, 29 independent melanoma patient samples (graded as primary in 
situ, regional metastatic, distant metastatic and nodal metastatic), and six normal skin samples 
were also analyzed using the same microarrays. Hierarchical clustering was used to represent 
the differential lncRNA expression profiles (Supplemental Fig. S1) and revealed potential 
signatures that could be used to discriminate between normal and melanoma samples. To select 
candidates for functional studies, we asked whether any of the differentially expressed lncRNAs 
in melanoma cell lines were also differentially expressed in patient samples. As a result we 
identified four candidate ncRNAs (AF085920, AK091731, AK128206, and AK024556), that were 
differentially expressed in both melanoma cell lines and patients samples relative to melanocytes 
and whose differential expression we were able to validate by next generation sequencing of 
polyadenylated RNA isolated from melanocytes and WM1552C cells (Supplemental Fig. S2; Fig. 
1A,B). We next examined the genomic context of the four lncRNA candidates and found that 
three of the lncRNAs (GenBank IDs AF085920, AK091731 and AK128206) mapped within a few 
kilobases of the 3’UTRs of known protein-coding genes and one (GenBank ID AK024556) 
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mapped within an intronic region (Supplemental Fig. S3). Due to the possibility of read-through 
expression from the upstream protein-coding genes and the complications in interpretation that 
this would create in subsequent studies to characterize these transcripts, we excluded the three 
lncRNAs that were positioned downstread of 3’UTRs from further study. Therefore, given the 
intronic position of the remaining candidate, which incidentally also had the highest degree of up-
regulation in melanoma cells compared to melanocytes (12-fold), we pursued this lncRNA for 
further study. AK024556 is a 687 nt unspliced, polyadenylated transcript originally identified in 
adipose tissue and is transcribed from the second intron of the SPRY4 gene (Fig. 1A), which led 
to our naming the transcript SPRY4-IT1. This region is not conserved beyond the primate 
genomes and there is no EST expression detected in mouse. Secondary structure prediction of 
the SPRY4-IT1 sequence indicates that this ncRNA transcript could fold into long stable hairpin 
structures (see below), suggesting that SPRY4-IT1 may function intrinsically as a RNA molecule. 
A comparison of SPRY4-IT1 in kidney, blood, and breast cell lines revealed expression to be 
equal to that of melanocytes or less (Supplemental Fig. S4). We then measured the expression 
levels of SPRY4-IT1 (Fig. 1C) as well as the SPRY4 ORF (Supplemental Fig. S5) in seven 
additional non-pigmented melanoma cell lines (WM793B, A375, SKMEL-2, RPMI 7951, HT-144, 
LOX-IMV1, and G361) by qRT-PCR and the results showed that the expression of both SPRY-
IN1 and SPRY4 was elevated in most of the melanoma cell lines relative to control melanocytes. 
Structural prediction of SPRY4-IT1 
To determine whether the SPRY4-IT1 RNA contained any particular secondary structural 
features, the SPRY4-IT1 genomic sequence was submitted to secondary structure and 
pseudoknot prediction (see Methods). Several helical regions are commonly predicted by both 
algorithms, including a large stem-loop from positions 220 to 321 (Fig. 1D). The latter 
encompasses one of two non-repeat associated “pyknons”, putative regulatory motifs that are 
non-randomly distributed throughout the genome (40). In addition, three putative pseudoknots 
(i.e., nested helices) are predicted by ProbKnot, which provides high sensitivity and positive 
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prediction rates (41). Consistent with the absence of expression of SPRY4-IT1 outside of 
primates, no compatible structures appear to be significantly conserved throughout a multiple 
alignment of orthologous sequences from 31 eutherian mammals (see Methods).  
Expression profiling of SPRY4 and SPRY4-IT1 in normal human tissue 
SPRY4 belongs to the Sprouty (SPRY) family of genes, which encode Ras/Erk inhibitor 
proteins. There are four SPRY genes (SPRY1, SPRY2, SPRY3 and SPRY4) in human (47, 48). 
Our next generation sequencing data shows that SPRY1 and SPRY3 have little or no expression 
in either melanoma or melanocytes, but both SPRY2 and SPRY4 are highly expressed in 
melanoma cells compared to melanocytes (Supplemental Fig. S5). Although the role of SPRY4 
has not been examined in melanoma, SPRY4 is down-regulated in non-small cell lung cancer 
and inhibits cell growth, migration, and invasion in transfected cell lines, suggesting it may 
function as a tumor suppressor (42). SPRY4 occurs in two alternately spliced isoforms, termed 
SPRY4.1 and SPRY4.2 (Fig. 1A), the latter of which includes an additional exon that results in 
translation initiation from an alternate start codon. To better understand where SPRY4 functions 
and the relative expression of the two isoforms, we used qRT-PCR to measure the expression of 
SPRY4.1 and SPRY4.2 across 20 human tissues (Supplemental Fig. S7). The results showed 
that both isoforms are expressed in all tissues examined, with the highest expression found in 
the lung and placenta, and the lowest in the thymus and oesophagus. SPRY4.1 was found to be 
the more abundant isoform, occurring in diverse ratios (relative to SPRY4.2) across different 
tissues, ranging from 2.7:1 in kidney to 28:1 in thyroid. Despite the differences in abundance, the 
expression profiles of SPRY4.1 and SPRY4.2 were predominantly positively correlated (R = 
0.75; Pearson correlation). 
Given the intronic position of SPRY4-IT1 within SPRY4, we next aimed to determine whether 
the expression of SPRY4-IT1 and SPRY4 were linked. Therefore, we examined the relative 
expression of SPRY4-IT1 across the same panel of 20 human tissues (Fig. 2A). Interestingly, we 
found that SPRY4-IT1 was more highly expressed than SPRY4.1 in several tissues, occurring at 
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ratios as high as 4.5:1 in kidney (Fig. 2B). Furthermore, the range in expression for SPRY4-IT1 
across the 20 different tissues was much greater than that of SPRY4; SPRY4-IT1 varied by as 
much as 111-fold (placenta vs oesophagus) compared to SPRY4.1, which varied by a maximum 
of ~10-fold (thyroid vs kidney). Despite the variation in abundance and range, the expression 
profile of SPRY4-IT1 was correlated with both SPRY4.1 (R = 0.62; Pearson correlation) and 
SPRY4.2 (R = 0.84; Pearson correlation). The similar expression profiles between SPRY4-IT1 
and SPRY4 suggest that SPRY4-IT1 and SPRY4 may share the same transcriptional regulatory 
factors. The two transcripts may either be transcribed independently from the same promoter or, 
alternatively, they may be transcribed as a single transcript, with SPRY4-IT1 then being 
processed directly from the intron of SPRY4. In the latter scenario, the higher abundance of 
SPRY4-IT1 could be explained by higher stability of the lncRNA relative to the mRNA. 
SPRY4-IT1 and SPRY4 expression in patient samples 
In light of the complex, though generally positively correlated, relationship between the 
SPRY4-IT1 and SPRY4 expression profiles, we next examined the expression of SPRY4-IT1 and 
SPRY4 in 25 melanoma patient samples using quantitative RT-PCR (Fig. 3A-D). We found that 
although the expression of both SPRY4-IT1 and SPRY4.2 varied considerably between patients 
samples, their relative expression levels were highly correlated (R = 0.95, Pearson correlation; 
Supplemental Fig. S8). The quantitative RT-PCR results also validated the microarray expression 
data, confirming that SPRY4-IT1 is consistently up-regulated in melanoma patient samples 
compared to the melanocyte control (Fig. 3A-D). 
Knockdown and localization of SPRY4-IT1 in melanoma cells  
To investigate the functional role of SPRY4-IT1, we used siRNA to down-regulate SPRY4-IT1 
expression in melanoma cells. Five different siRNA molecules were tested for their knockdown 
efficiency, the most efficient of which (siRNA 594) was selected for subsequent biological studies. 
To determine the optimal concentration for knockdown, several different concentrations of siRNA 
were examined in the melanoma cell lines A375 and WM1552C (Fig. 4A,B). When these cells 
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were transfected with 6 nM of siRNA, a 45% SPRY4-IT1 silencing was observed in A375 cells, 
but no significant changes were observed in WM1552C cells. However, 18 nM of siRNA yielded 
at least 60% knockdown in both cell lines (WM1552C and A375). These results were validated by 
Northern blot analysis (Fig. 4C). Although we saw a high level of SPRY4-IT1 knockdown with 30 
nM siRNA, we also saw significant cell death (data not shown). Therefore, subsequent cell 
biology studies were performed with a maximum of 18 nM siRNA. 
Given the correlated expression of SPRY4-IT1 and SPRY4, we next aimed to determine the 
effect of SPRY4-IT1 knockdown on SPRY4 expression in A375 cells. Using qRT-PCR, we 
determined the expression of SPRY4 following siRNA-mediated knockdown of SPRY4-IT1. As a 
result, we found that the level of SPRY4 expression was not significantly altered following 
SPRY4-IT1 knockdown relative to the Scrambled siRNATM siRNA control (Supplemental Fig. S9). 
This result confirms that the RNAi knockdown strategy did not appreciably affect the levels of the 
host SPRY4 transcript and that the phenotypic effects observed following knockdown of SPRY4-
IT1 were driven directly by SPRY4-IT1. Furthermore, the result shows that SPRY4-IT1 does not 
regulate SPRY4 expression. 
Next, we examined the expression of lncRNA SPRY4-IT1 in A375 cell lines and melanocytes 
by in situ hybridization using a locked nucleic acid (LNA) FAM-labeled probe (see Methods). RNA 
FISH showed that SPRY4-IT1 is localized as a punctate pattern in the nucleus, but the majority of 
the signal was observed in the cell cytoplasm (Fig. 4D). Consistent with the above mentioned 
qRT-PCR results (Fig. 1C), RNA FISH also revealed that SPRY4-IT1 was highly expressed in 
A375 melanoma cells compared to melanocytes. The dose-dependent reduction of RNA-FISH 
signal in A375 cells transfected with different concentrations of SPRY4-IT1-targeted siRNAs show 
that the probe was specifically detecting the SPRY4-IT1 transcript. 
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Modulation of SPRY4-IT1 expression effects metabolic viability, cell death, cell invasion 
and cell migration  
To investigate the possible role of SPRY4-IT1 on the growth of melanoma cells, the metabolic 
viability was assessed using a colorimetric assay, which involves the conversion of MTT in active 
mitochondria of living cells to formazan. The amount of formazan correlates with the number of 
viable cells. A375 melanoma cells knocked-down with siRNA showed a 50% decrease in 
metabolic viability 48 h after transfection, whereas WM1552C cells showed a 30% decrease in 
viability (Fig. 5A,B). The MTT assay demonstrates that the down-regulation of SPRY4-IT1 
expression decreases cell growth in melanoma cells. Next, we investigated the effects of SPRY4-
IT1 knockdown on apoptosis. Apoptosis was detected by labeling phosphotidylserine using FITC-
conjugated Annexin V in unfixed cells (43). The percentage of Annexin V positive-negative and PI 
positive-negative cells was estimated by gating the cell population. A375-untreated or Scrambled 
siRNATM siRNA-treated cells showed minimal annexin positive cells 48 h after transfection (Fig. 
5C). The fraction of annexin positive cells with 6 nM of siRNA was 9%. This was increased to 
26% at 12 nM and 53% when 18 nM of siRNA used for transfection. Interestingly, no major 
differences were observed in propidium iodide-positive cells indicating that the knockdown of 
SPRY4-IT1 induces cell death primarily through apoptosis, not necrosis. We also examined the 
effect of SPRY4-IT1 knockdown on the invasion of A375 melanoma cells (Fig. 5D,E). The results 
of the invasion assay demonstrates that knockdown of SPRY4-IT1 inhibits melanoma cell 
invasion by greater than 60% at 6 nM of siRNA and greater than 80% at 12 and 18 nM. This 
invasion defect is significant, even accounting for defects due to the loss of cell viability (> 80% 
invasion defect at 12 and 18 nM siRNA with only a 50% loss of cell viability). To investigate the 
independent effects of knock down and upregulation of SPRY4-IT1 on cell migration, we utilized 
the in vitro scratch assay. The effect of SPRY4-IT1 knockdown on cell motility was assessed on 
WM1552C cells transfected with SPRY4-IT1 siRNA compared to cells transfected with Scrambled 
siRNATM siRNA. The percentage surface area between wounds was determined at 4 h intervals 
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from 0 to 24 h. Comparison between the SPRY4-IT1 and Scrambled siRNATM siRNA cells 
indicated a decreased mobility of the SPRY4-IT1 siRNA-transfected cells with the most 
pronounced effect observed at t = 16 (p= 0.0013) (Fig. 5F; Supplemental Fig. S10). The effect of 
upregulation of SPRY4-IT1 on cell migration was assessed on LOX IMV1 cells, which have a 
comparatively low level of endogenous SPRY4-IT1 expression (Fig. 1C).  Comparison of the 
percentage surface area between wounds of pcDNA6/SPRY4-IT1 or pcDNA6 vector only 
transfected LOX IMV1 cells, respectively, was determined at 2 h intervals from 0 to 24 h. The 
pcDNA6/SPRY4-IT1 transfected cells showed an immediate increase in mobility with the most 
pronounced effect being observed at t=6 (p<0.0001) and wound closure occurring at 10 h as 
compared to 22 h for the vector transfected cells (Fig. 5G; Supplemental Fig. S10).  
 
DISCUSSION 
In this study, we report the identification of melanoma-specific lncRNAs and characterization 
of one such transcript, SPRY4-IT1 (Genbank accession ID AK024556) in melanoma cell lines and 
patient samples. SPRY4-IT1 is derived from an intron of the Sprouty 4 (SPRY4) gene and is 
predicted to contain several long hairpins in its secondary structure. Knockdown of SPRY4-IT1 
expression results in defects in cell growth, decreased invasion and increased rates of apoptosis 
in melanoma cells. A decreased capacity for cell migration was also observed for SPRY4-IT1 
knockdown whilst a converse increase in speed of migration was noted for a melanoma cell line 
overexpressing SPRY4-IT1. Together with the increased expression of SPRY4-IT1 in melanoma 
cells and patient samples compared to melanocytes, we suggest that SPRY4-IT1 may play an 
important role in melanoma pathogenesis in human. 
Although the functional significance of miRNAs is now well known, little is understood about 
the functionality of most lncRNAs. Nevertheless, the growing catalogue of functionally 
characterized lncRNAs reveals that these transcripts are important in different physiological 
processes, including embryonic stem cell differentiation (7), T-cell differentiation (44), 
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oligodendrogenesis (19), and keratinocyte differentiation (45), and altered expression of lncRNAs 
could result in cancer (46). Recently, the long intergenic RNA HOTAIR was shown to regulate 
metastatic progression in human breast cancer. This RNA recruits Polycomb Repressive 
Complex 2 to specific target genes in the genome that lead to H3K27 trimethylation and 
epigenetic silencing of metastatic suppressor genes (33). Interestingly, the majority of lncRNAs 
are transcribed close to or within protein-coding loci, which has prompted the hypothesis that 
lncRNAs may have cis-acting effects within these loci. Indeed, a number of studied lncRNAs, 
such as Evf2 and p15as, have fitted this model by influencing the expression (either positively or 
negatively) of the local protein-coding gene. Apart from intronically derived small RNAs, such as 
some snoRNAs and miRNAs, the role of other intronic ncRNAs is unknown. 
Previous large-scale analyses examining the relative expression of protein-coding genes and 
associated intronic lncRNAs have revealed that, although there is a general trend that the 
expression of the host gene and the intronic ncRNA are positively correlated, the relationship is 
seldom exclusive (3, 7). As an illustrative example, the expression of Odz3 and its associated 
intronic lncRNA are localized to the hippocampus of the adult mouse brain, but while Odz3 is 
expressed only in the CA1 subfield, the ncRNA is expressed throughout all hippocampal subfields 
(3). Such an expression profile suggests that intronic lncRNAs are not simply co-expressed with 
the host mRNA, but rather that there is some independence in their regulatory control 
mechanisms. This resonates with the comparative expression profiles of SPRY4-IT1 and the host 
gene SPRY4, whose expression is correlated across most tissues, but is highly divergent in some 
others, such as kidney where it is expressed at 4.5-fold higher levels than SPRY4. Nevertheless, 
the generally similar expression profiles, which are suggestive of shared regulatory mechanisms, 
is consistent with the notion that the function of SPRY4-IT1 is likely to be related to the biological 
pathway of SPRY4. 
SPRY4, a member of the Ras/Erk inhibitor encoding Sprouty family of genes, is an inhibitor of 
the receptor-transduced mitogen-activated protein kinase (MAPK) signaling pathway. It functions 
 16 
upstream of RAS activation and impairs the formation of active GTP-RAS (49). Previous studies 
have reported SPRY4 mRNA expression to be decreased in non-small cell lung cancer (NSCLC) 
cell lines, with SPRY4 shRNA knockdown showing increased cell growth. Conversely, stable 
transfection of SPRY4 in NSCLC cell lines lead to reduced cell growth, migration, and invasion. 
Together, these results indicate a putative tumour suppressor role for SPRY4 (42). The intronic 
positioning of SPRY4-IT1 within SPRY4, coupled with the largely shared expression profiles, 
raise the hypothesis that SPRY4-IT1 may also be involved in the MAPK-signaling pathway, which 
would be consistent with the defects in cell growth, migration, differentiation and increased rates 
of apoptosis in melanoma cells following its knockdown. Examination of in silico pathway maps 
indicate that SPRY4-IN1 interacts with Raf1, B-Raf, MEK1/2, TESK1, MARKK, and MARK2, 
further supporting the notion that SPRY4-IN1 may effect MAPK-signaling. Further investigation is 
currently underway to determine whether or not SPRY4-IT1 is indeed involved in the MAPK 
signaling pathway. 
Previous examinations of lncRNAs have shown that many are localized to specific subcellular 
compartments (3, 4). The subcellular location of RNA can provide important insight into its 
potential function. For example, the lncRNA MEN / is localized to nuclear paraspeckles, which 
is a nuclear domain thought to be involved in various aspects of RNA processing. Using 
fluorescent in situ hybridization, we found that SPRY4-IT1 was localized to the cytoplasm. 
Although the majority of functionally characterized lncRNAs are nuclear-localized, it has been 
previously noted that many lncRNAs are transported to the cytoplasm (50). Within the cytoplasm, 
it is possible that the lncRNAs are functioning as protein-scaffolds or as signaling molecules. 
Determination of any proteins interacting with SPRY4-IN will be important in elucidating its role 
and put additional context to its cellular localization. 
In summary, we have shown that SPRY4-IT1 expression is substantially increased in patient 
melanoma cell samples  compared to melanocytes. The elevated expression of SPRY4-IT1 in 
melanoma cells, its accumulation in cell cytoplasm, and effects on cell dynamics suggest that the 
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mis-expression of SPRY4-IT1 may have an important role in melanoma development, and could 
be an early biomarker and a key regulator for melanoma pathogenesis in human.  
 
ACKNOWLEDGMENTS 
This work was supported by an Australian Research Council / University of Queensland co-
sponsored Federation Fellowship (FF0561986; JSM), a National Health and Medical Research 
Council of Australia (NHMRC) Career Development Award (CDA631542; MED), and a 
Queensland Government Department of Employment, Economic Development and Innovation 
Smart Futures Fellowship (MED). We thank Dr. James Goydos (UMDNJ-Robert Wood Johnson 
Medical School) for clinical samples and Dr. Ravichandran (Life Technologies) for siRNA and Dr. 
Nathan Salamonis (UCSF) for preliminary data analysis. 
  
 18 
REFERENCES 
1. Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The 
transcriptional landscape of the mammalian genome. Science. 2005;309:1559-63. 
2. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, et al. Transcriptional maps 
of 10 human chromosomes at 5-nucleotide resolution. Science. 2005;308:1149-54. 
3. Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS. Specific expression of long 
noncoding RNAs in the mouse brain. Proc Natl Acad Sci U S A. 2008;105:716-21. 
4. Sunwoo H, Dinger ME, Wilusz JE, Amaral PP, Mattick JS, Spector DL. MEN 
varepsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation 
and are essential components of paraspeckles. Genome Res. 2009;19:347-59. 
5. Amaral PP, Mattick JS. Noncoding RNA in development. Mamm Genome. 2008;19:454-
92. 
6. Blackshaw S, Harpavat S, Trimarchi J, Cai L, Huang H, Kuo WP, et al. Genomic analysis 
of mouse retinal development. PLoS Biol. 2004;2:E247. 
7. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, et al. Long 
noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 
2008;18:1433-45. 
8. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional 
demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 
2007;129:1311-23. 
9. Pollard KS, Salama SR, King B, Kern AD, Dreszer T, Katzman S, et al. Forces shaping 
the fastest evolving regions in the human genome. PLoS Genet. 2006;2:e168. 
10. Pheasant M, Mattick JS. Raising the estimate of functional human sequences. Genome 
Res. 2007;17:1245-53. 
 19 
11. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature 
reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 
2009;458:223-7. 
12. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat 
RNA to the mouse X chromosome. Science. 2008;322:750-6. 
13. Prasanth KV, Spector DL. Eukaryotic regulatory RNAs: an answer to the 'genome 
complexity' conundrum. Genes Dev. 2007;21:11-42. 
14. Espinoza CA, Allen TA, Hieb AR, Kugel JF, Goodrich JA. B2 RNA binds directly to RNA 
polymerase II to repress transcript synthesis. Nat Struct Mol Biol. 2004;11:822-9. 
15. Mariner PD, Walters RD, Espinoza CA, Drullinger LF, Wagner SD, Kugel JF, et al. Human 
Alu RNA is a modular transacting repressor of mRNA transcription during heat shock. Mol Cell. 
2008;29:499-509. 
16. Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF. RNA regulation of epigenetic 
processes. Bioessays. 2009;31:51-9. 
17. Fejes-Toth K, Sotirova V, Sachidanandam R, Assaf G, Hannon GJ, Kapranov P, et al. 
Post-transcriptional processing generates a diversity of 5'-modified long and short RNAs. Nature. 
2009;457:1028-32. 
18. Mercer TR, Dinger ME, Bracken CP, Kolle G, Szubert JM, Korbie DJ, et al. Regulated 
post-transcriptional RNA cleavage diversifies the eukaryotic transcriptome. Genome Res. 
2010;20:1639-50. 
19. Mercer TR, Qureshi IA, Gokhan S, Dinger ME, Li G, Mattick JS, et al. Long noncoding 
RNAs in neuronal-glial fate specification and oligodendrocyte lineage maturation. BMC Neurosci. 
2010;11:14. 
20. Zhao J, Sinclair J, Houghton J, Bolton E, Bradley A, Lever A. Cytomegalovirus beta2.7 
RNA transcript protects endothelial cells against apoptosis during ischemia/reperfusion injury. J 
Heart Lung Transplant. 2010;29:342-5. 
 20 
21. Ishii N, Ozaki K, Sato H, Mizuno H, Saito S, Takahashi A, et al. Identification of a novel 
non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51:1087-
99. 
22. Faghihi MA, Modarresi F, Khalil AM, Wood DE, Sahagan BG, Morgan TE, et al. 
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward 
regulation of beta-secretase. Nat Med. 2008;14:723-30. 
23. Sonkoly E, Bata-Csorgo Z, Pivarcsi A, Polyanka H, Kenderessy-Szabo A, Molnar G, et al. 
Identification and characterization of a novel, psoriasis susceptibility-related noncoding RNA 
gene, PRINS. J Biol Chem. 2005;280:24159-67. 
24. Daughters RS, Tuttle DL, Gao W, Ikeda Y, Moseley ML, Ebner TJ, et al. RNA gain-of-
function in spinocerebellar ataxia type 8. PLoS Genet. 2009;5:e1000600. 
25. Woo CJ, Kingston RE. HOTAIR lifts noncoding RNAs to new levels. Cell. 2007;129:1257-
9. 
26. Pibouin L, Villaudy J, Ferbus D, Muleris M, Prosperi MT, Remvikos Y, et al. Cloning of the 
mRNA of overexpression in colon carcinoma-1: a sequence overexpressed in a subset of colon 
carcinomas. Cancer Genet Cytogenet. 2002;133:55-60. 
27. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S. Regulation of apoptosis by a 
prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 
2006;25:135-41. 
28. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, et al. Ultraconserved 
regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 
2007;12:215-29. 
29. Lin R, Maeda S, Liu C, Karin M, Edgington TS. A large noncoding RNA is a marker for 
murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene. 
2007;26:851-8. 
 21 
30. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. 
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 
2002;62:2695-8. 
31. Li L, Feng T, Lian Y, Zhang G, Garen A, Song X. Role of human noncoding RNAs in the 
control of tumorigenesis. Proc Natl Acad Sci U S A. 2009;106:12956-61. 
32. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic 
silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202-6. 
33. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA 
HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071-6. 
34. Hofacker IL. RNA secondary structure analysis using the Vienna RNA package. Curr 
Protoc Bioinformatics. 2004;Chapter 12:Unit 12 2. 
35. Reuter JS, Mathews DH. RNAstructure: software for RNA secondary structure prediction 
and analysis. BMC Bioinformatics. 2010;11:129. 
36. Gruber AR, Findeiss S, Washietl S, Hofacker IL, Stadler PF. Rnaz 2.0: Improved 
Noncoding Rna Detection. Pac Symp Biocomput. 2010;15:69-79. 
37. Gesell T, Washietl S. Dinucleotide controlled null models for comparative RNA gene 
prediction. BMC Bioinformatics. 2008;9:248. 
38. Katoh K, Asimenos G, Toh H. Multiple alignment of DNA sequences with MAFFT. 
Methods Mol Biol. 2009;537:39-64. 
39. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, et al. The regulation 
of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One. 2010;5:e13779. 
40. Tsirigos A, Rigoutsos I. Human and mouse introns are linked to the same processes and 
functions through each genome's most frequent non-conserved motifs. Nucleic Acids Res. 
2008;36:3484-93. 
41. Bellaousov S, Mathews DH. ProbKnot: Fast prediction of RNA secondary structure 
including pseudoknots. RNA. 2010;16:1870-80. 
 22 
42. Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA, Winn RA. 
Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal 
transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol 
Cancer Res. 2010;8:833-43. 
43. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells 
using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39-51. 
44. Pang KC, Dinger ME, Mercer TR, Malquori L, Grimmond SM, Chen W, et al. Genome-
wide identification of long noncoding RNAs in CD8+ T cells. J Immunol. 2009;182:7738-48. 
45. Mazar J, Sinha S, Dinger ME, Mattick JS, Perera RJ. Protein-coding and non-coding gene 
expression analysis in differentiating human keratinocytes using a three-dimensional epidermal 
equivalent. Mol Genet Genomics. 2010;284:1-9. 
46. Hall PA, Russell SH. New perspectives on neoplasia and the RNA world. Hematol Oncol. 
2005;23:49-53. 
47. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, et al. Sprouty 2, an inhibitor of 
mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. 
Cancer Res. 2006;66:2048-58. 
48. Lo TL, Fong CW, Yusoff P, McKie AB, Chua MS, Leung HY, et al. Sprouty and cancer: the 
first terms report. Cancer Lett. 2006;242:141-50. 
49. Leeksma OC, Van Achterberg TA, Tsumura Y, Toshima J, Eldering E, Kroes WG, et al. 
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. 
Eur J Biochem. 2002;269:2546-56. 
50. Barthelson RA, Lambert GM, Vanier C, Lynch RM, Galbraith DW. Comparison of the 
contributions of the nuclear and cytoplasmic compartments to global gene expression in human 
cells. BMC Genomics. 2007;8:340. 
 23 
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Genomic context, expression profile in melanoma cell lines and secondary 
structure of SPRY4-IT1. (A) Genome browser view of the SPRY4 locus showing the two 
annotated isoforms of SPRY4 (SPRY4.1 and SPRY4.2) and the position of the lncRNA SPRY4-
IT1, within the second intron of SPRY4.2. Arrows indicate the direction of transcription. (B) Next-
generation cDNA sequencing data illustrates the expression levels of AK024556 (SPRY4-IT1). 
The upper panel depicts the transcript numbers in melanocytes and the lower panel shows the 
transcript level in WM1552C. (C) Expression of SPRY4-IT1 in eight melanoma cell lines, 
keratinocytes, and melanocytes, as determined qRT-PCR. Error bars indicate the standard error 
of the mean for three technical replicates. Expression values are normalized to 1 in melanocytes. 
(D) Computational prediction of the secondary structure of the SPRY4-IT1 transcript, as 
determined by RNAfold and RNAstructure (see Methods). Blue lines indicate positions of pseudo 
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knots. Red base-pairing indicates regions of consensus structure between the two algorithms. 
The contour of the large stem loop is highlighted in red, while the position of the two pyknons are 
outlined in green. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Expression of SPRY4-IT1 and SPRY4 in 20 normal human tissues. (A) Expression 
of SPRY4-IT1 relative to the housekeeping control gene RPLO in 20 normal human tissues, as 
determined qRT-PCR. Error bars indicate the standard error of the mean for three technical 
replicates. (B) Ratios of SPRY4-IT1 to SPRY4.1 across 20 normal human tissues. The 
expression of SPRY4.1 was determined using qRT-PCR using RPLO as the control gene (see 
Figure S1 for SPRY4.1 and SPRY4.2 expression data). 
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Figure 3. SPRY4-IT1 expression in melanoma patients. (A-D) Measure of the relative expression 
of SPRY4-IT1 in primary (A), nodal metastasis (B), regional metastasis (C), and distant 
metastasis (D) in melanoma patient samples. The patient samples are arbitrarily numbered. Gene 
expression values were determined by qRT-PCR and error bars indicate the standard error of the 
mean for three technical replicates. All expression values are normalized to 1 in melanocytes. 
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Figure 4. Knockdown and subcellular localization of SPRY4-IT1 in melanoma cells and 
melanocytes. (A, B) Expression of SPRY4-IT1 following knockdown by siRNA at different 
concentrations (6 nM, 12 nM and 18 nM) in the melanoma cell lines A375 (A) and WM1552C (B). 
The level of knockdown efficiency was determined by qRT-PCR. Error bars indicate the standard 
error of the mean for three technical replicates and expression values are normalized to 1 in the 
respective Scramble siRNA controls. (C) Validation of siRNA knockdown by Northern blot 
analysis using a probe specific to SPRY4-IT1. U6 RNA was used as a load control. (D) 
Localization of SPRY4-IT1 by RNA-FISH in melanocytes and A375-transfected cells with SPRY4-
IT1-targeted siRNA (or Scrambled siRNATM siRNA) at various concentrations. Nuclei are stained 
blue (DAPI) and SPRY4-IT1 is stained green. Magnification is 60X with 4.5X zoom.  
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Figure 5. Modulation of SPRY4-IT1 expression effects metabolic viability, cell death, cell 
invasion and cell migration in melanoma cells. (A, B) SPRY4-IT1 knockdown reduces viability 
of A375 or WM1552C melanoma cells. Viability of cells transfected with either SPRY4-IT1-
targeted siRNA or Scrambled siRNATM siRNA was determined by MTT assay. Each bar 
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represents triplicate analyses of mean ± S.D., where the significant difference from the scrambled 
control is represented by an asterisk (p < 0.008) (C) Knockdown of SPRY4-IT1 induced 
apoptosis. Cells treated for 48 h with either Scrambled siRNATM siRNA or SPRY4-IT1-targeted 
siRNA were stained for Annexin V/PI and analyzed by flow cytometry. The percentage of cells 
positive for Annexin V and PI staining are presented in each quadrant. (D & E) The invasive 
potential of SPRY4-IT1 siRNA knockdown in A375 cells was examined by Matrigel invasion assay 
(visual field representative of one experiment). Representative numbers of invading cells through 
the Matrigel were counted using Aperio software. Each bar represents the mean ± S.D. of counts 
from three membranes. Significantly reduced invasion in SPRY4-IT1-targeted siRNA as 
compared to Scrambled siRNATM siRNA is indicated by asterisks (p < 0.049). (F, G) The 
migration potential of cells with altered SPRY4-IT1 expression was examined by a wound healing 
assay. Comparison of cell motility of WM1552C cells transfected with either SPRY4-IT1-targeted 
siRNA or Scrambled siRNATM siRNA (F) and LOX IMV1 cells transfected with pcDNA6/SPRY4-
IT1 or empty pcDNA6/V5-HisA vector (G) was followed, starting at 0 h and continuing through to 
24 h. The percent surface area between the wounds was determined using NIS elements 
software. Each time point was compared to the “0 h” time point of their respective cells. 
Quantification of wound healing was based on triplicate assays with error bars indicating the 
standard error of the mean. 
 
 
